Ro GLP-1 Program: Medications, Cost, and How It Works

What Is Ro, and What GLP-1s Does It Actually Prescribe?

Ro (Roman Health Ventures Inc., trading as Ro) is a direct-to-consumer telehealth company founded in 2017. You complete an online medical history, a licensed provider reviews it, and if you qualify, a prescription is routed to a pharmacy that ships to you. The weight-management arm is branded Ro Body.

As of August 2026, Ro's published GLP-1 lineup consists of FDA-approved branded medication only:

• Wegovy (semaglutide) pen, the once-weekly injection approved by the FDA in June 2021 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbid condition.
• Wegovy pill, the 25 mg once-daily oral form of semaglutide approved in December 2025, the first oral GLP-1 cleared for weight management. Oral semaglutide has strict timing rules: take it on an empty stomach after waking with no more than about 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other oral medicines.
• Zepbound (tirzepatide), approved November 8, 2023 for chronic weight management in adults at the same two BMI thresholds. Its current label also carries a second indication, for moderate-to-severe obstructive sleep apnea in adults with obesity.
• Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1, FDA-approved in April 2026. It is a small molecule rather than a peptide, and its label directs taking it once daily with or without food, with no water restriction or waiting period.

Earlier in the GLP-1 shortage era, through 2025 and into early 2026, Ro also offered compounded semaglutide and tirzepatide. That is no longer part of the offer. Section five covers why the whole category moved. Ozempic prescribed off-label and Saxenda appear in some older third-party reviews of Ro; neither is in the current published lineup, so do not assume either is available without asking.

The Ro Body membership model

This is the structural point worth understanding before any price comparison. Ro charges a recurring membership fee for the service layer: provider review, ongoing check-ins, refill management, and help pursuing insurance coverage. The medication is a separate charge on top. Your real monthly number is the sum of the two, and only the second half is drug cost.

That structure is common across direct-to-consumer telehealth, not unique to Ro. It matters because a headline medication price from a telehealth platform is not comparable to a pharmacy or manufacturer price until you add the membership back in.

Ro GLP-1 Pricing as of May 2026

The figures below come from The Rx Index, an independent pricing aggregator, in a guide published May 7, 2026 and linked in the references below. They were accurate to that snapshot and are reproduced here as a structural reference, not as today's rates. Ro's own site is the only current authority on what you will actually be charged.

Membership and medication, as reported in May 2026

Telehealth GLP-1 pricing is two layers: the membership fee for the service, plus the medication charge itself.

How this compares to going direct to the manufacturer

Eli Lilly's own Self Pay Journey Program, under its terms effective February 23, 2026, prices Zepbound at $299/month for 2.5 mg, $399/month for 5 mg, and $449/month for doses from 7.5 mg through 15 mg, on both the single-dose vial and the KwikPen. Ro's reported Zepbound tiers were the same three numbers.

So the drug is priced at roughly the manufacturer's cash rate either way, and the membership fee is the added cost of the telehealth layer. What that fee buys is a prescriber you can reach online, refill handling, and coverage support. Whether that is worth it depends on how easily you can get an in-person prescription. Our LillyDirect Zepbound self-pay guide walks through the manufacturer-direct route in full, including the 45-day refill condition attached to the $449 tier.

For scale: the Zepbound list price is roughly $1,086 per month (Lilly's published WAC pricing, 2026) without a program or insurance. Both routes discussed here sit far below that.

Is Ro Legit? What the Prescribing Process Involves

Ro is an established company that has been operating since 2017 and works with licensed U.S. providers. Its GLP-1 program dispenses FDA-approved branded medication through licensed pharmacies. On the structural questions of "is this a real pharmacy operation," the answer is straightforward.

The more useful question is how much clinical review sits behind the prescription, and that question applies to every direct-to-consumer platform, including this one. The typical flow looks like this:

The standard direct-to-consumer GLP-1 path: online intake, provider review, prescription, pharmacy fulfillment.

Eligibility follows the medication's FDA-approved indication, and the wording has shifted over time, so check the current one rather than a number you read somewhere. The Zepbound approval announcement describes adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, giving high blood pressure, type 2 diabetes, and high cholesterol as its examples. Wegovy's original 2021 prescribing information set out the same two thresholds, with hypertension, type 2 diabetes, and dyslipidemia as its examples; the current Wegovy label states obesity, or overweight with at least one weight-related comorbid condition, without numeric thresholds. Any prescriber, online or in person, is working from the current criteria.

One thing worth knowing if sleep apnea is part of your picture: Zepbound's current label carries a second indication beyond weight management, for moderate-to-severe obstructive sleep apnea in adults with obesity. That is a separate approved use with its own eligibility, not a comorbidity that qualifies you under the weight-management indication.

What the research says about telehealth GLP-1 oversight generally

A secret-shopper study published in JAMA in July 2026 examined 49 direct-to-consumer platforms selling GLP-1 medications. Across those sites, 91.8% issued a prescription. Only 26.5% required a video visit and 6.1% a phone call, which means roughly two-thirds prescribed with no clinician interaction at all. The study did not name individual platforms and says nothing about Ro specifically. What it does establish is that the depth of clinical review varies enormously across this category, and that a prescription arriving quickly is not by itself evidence that anyone looked closely.

So ask any telehealth provider one question before you pay: will a clinician actually read my history, and will someone be reachable when a dose causes trouble. Titration produces real side effects. The answer to that question is what a membership fee is buying you.

Insurance and Coverage Through Ro

Ro's program is reported to include insurance-navigation support for the branded medication: checking whether your plan lists the drug, and helping pursue prior authorization where the plan requires it. The Rx Index guide is the source for that, and it notes the same coordination was not offered for compounded product. Because the lineup is FDA-approved branded product, coverage is at least theoretically on the table, which was effectively never available for compounded product.

Two limits are worth knowing up front. First, the membership fee itself is a service charge and is typically not reimbursable by insurance, so it stays out of pocket even in the best case. Second, whether the drug is covered is decided entirely by your plan's formulary and its prior-authorization rules, not by the platform. Many employer plans still exclude weight-management drugs outright.

If you do have commercial coverage, manufacturer savings cards are usually the cheaper route than any cash-pay program. The Zepbound savings card guide and the Wegovy savings card guide cover how those work and who qualifies.

Does Ro Still Offer Compounded Semaglutide or Tirzepatide?

No. As of the most recent published information checked in August 2026, Ro's GLP-1 offering is FDA-approved branded medication only. Compounded semaglutide and tirzepatide are not part of the current lineup.

The reason is regulatory rather than commercial. Compounded GLP-1s were widely available while the branded products sat on the FDA shortage list, because shortage status opens a legal pathway for compounding pharmacies. Once the shortages resolved, that pathway narrowed sharply, and manufacturer litigation put further pressure on telehealth platforms marketing compounded copies. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, with a comment period that ran through June 29, 2026. That proposal would remove the remaining route for outsourcing facilities to compound these three molecules at scale.

The direction of travel across the industry has been consistent through 2026: platforms that once marketed compounded GLP-1s have moved to branded product. If you are researching the compounded route specifically, our guides to compounded semaglutide and compounded tirzepatide cover the current legal picture and the quality questions in detail.

Ro GLP-1 vs. Other Ways to Get a Prescription

There are three broad routes to an FDA-approved GLP-1, and they trade off differently on cost, speed, and clinical depth.

A reasonable order of operations: check your insurance formulary first, since covered access with a savings card usually beats every cash route. If there is no coverage and you already have a prescriber, manufacturer-direct self-pay avoids the membership layer entirely. If you have neither coverage nor a prescriber willing to write the script, a telehealth membership is what the fee is actually solving. New to the category? Start with our getting started with GLP-1 medications guide, and see Ozempic vs. Wegovy for background on the branded semaglutide products.